Kanglin Bioteck Ltd. Inc.
Haoquan Wu obtained his Ph.D. from Fudan University at 2000. After his postdoc training in UCLA and Harvard medical school, he joined Texas Tech University Health Science Center at El Paso as a tenure-track assistant professor at 2009. He was promoted to Associate professor at 2015 and promoted to professor at 2018 in City of Hope. His major research area are miRNA biogenesis, siRNA/shRNA optimization, CRISPR-Cas9-based genome-wide screening and developing shRNA-based HIV therapy. Dr. Wu founded Kanglin Biotech Ltd. Inc. at 2015, which is focusing on developing gene therapy for various diseases, such as HIV, Parkinson’s disease, Thalassemia and hemophilia.